The study was carried out to investigate the thrombolytic and anti-inflammatory potentials of crude
50% ethanolic extracts of leaves of Hevea brasiliensis, using an in-vitro clot lysis and protein
denaturation method. The thrombolytic potentials of the crude 50% ethanolic extract was performed
in different concentrations (100, 200, 300, 400, and 500 ?l) using five (05) different nature of human
blood samples. Blood samples were gathered from Tripura's youthful volunteers, North East India,
and streptokinase was taken as the standard drug and distilled water as the negative control for the
validation of the method. The albumin denaturation assay was performed to assess anti-inflammatory
activity in-vitro. A greater clot lysis result was obtained, i.e., 37.8±0.8 %, 43.3±0.48 %, 51.4±0.33%,
65.4±0.79%, and 75.3±0.98 % at 100, 200, 300, 400, and 500 ?l concentrations, correspondingly
while the standard drug (streptokinase) showed 49.06±0.93%, 58.5±0.48%, 64.7±0.7%, 73.1±0.56%,
82.8±0.71% clot lysis. Inhibition of protein denaturation was seen in the in-vitro anti-inflammatory
effect of a 50% ethanol extract of Hevea brasiliensis, i.e., 46.1±0.11, 56.03± 0.76,65.7±0.52,
70.7±0.5, 74.7±0.27 at 100, 200, 300, 400, and 500 ?l respectively whereas, standard (aspirin) was
recorded at 56.4±0.31, 65.6±0.71, 70.5±0.43, 75.1±0.21, 80.1±0.18 at similar various concentrations.
Specific polar phytoconstituents may be the cause of the considerable in-vitro thrombolytic and anti-
inflammatory outcomes that were observed. The preliminary estimations of 50% ethanolic extractof Hevea brasiliensis have been proven the presence of polyphenols and ethanol-soluble flavonoids.
However, in-vivo thrombolytic, anti-inflammatory potentiality, and active component(s) of the extract
are yet to be discovered.
Keywords: Hevea brasiliensis, in-vitro thrombolytic, anti-inflammatory activity
Publication date: 01/01/2024
https://ijbpas.com/pdf/2024/January/MS_IJBPAS_2024_7416.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.1.7416
